liver diseases

Summary

Summary: Pathological processes of the LIVER.

Top Publications

  1. pmc Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management
    Raj Vuppalanchi
    Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Hepatology 49:306-17. 2009
  2. ncbi Autophagy in liver diseases
    Pierre Emmanuel Rautou
    Service d Hepatologie, Hopital Beaujon, Assistance Publique Hopitaux de Paris, Clichy, France
    J Hepatol 53:1123-34. 2010
  3. ncbi Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008
    Zobair M Younossi
    Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, Virginia, USA
    Clin Gastroenterol Hepatol 9:524-530.e1; quiz e60. 2011
  4. ncbi MiR-122 in hepatic function and liver diseases
    Jun Hu
    CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences CAS, Beijing 100101, China
    Protein Cell 3:364-71. 2012
  5. ncbi Adipokines in liver diseases
    Fabio Marra
    Department of Internal Medicine, University of Florence, Florence, Italy
    Hepatology 50:957-69. 2009
  6. ncbi Inflammatory pathways in liver homeostasis and liver injury
    Frank Tacke
    Medical Clinic III, RWTH University Hospital Aachen, Pauwelsstrasse 30, 52074, Aachen, Germany
    Clin Rev Allergy Immunol 36:4-12. 2009
  7. ncbi IFATS collection: in vivo therapeutic potential of human adipose tissue mesenchymal stem cells after transplantation into mice with liver injury
    Agnieszka Banas
    Section for Studies on Metastasis, National Cancer Center Research Institute, Tokyo, Japan
    Stem Cells 26:2705-12. 2008
  8. ncbi First identification of the hepatotoxic microcystins in the serum of a chronically exposed human population together with indication of hepatocellular damage
    Jun Chen
    Donghu Experimental Station of Lake Ecosystems, State Key Laboratory of Freshwater Ecology and Biotechnology of China, Institute of Hydrobiology, Chinese Academy of Sciences, P R China
    Toxicol Sci 108:81-9. 2009
  9. ncbi Acetaminophen-induced hepatotoxicity
    Laura P James
    Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
    Drug Metab Dispos 31:1499-506. 2003
  10. ncbi Drug-induced hepatotoxicity
    William M Lee
    Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390 9151, USA
    N Engl J Med 349:474-85. 2003

Detail Information

Publications376 found, 100 shown here

  1. pmc Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management
    Raj Vuppalanchi
    Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Hepatology 49:306-17. 2009
    ..Several recent studies have highlighted that cardiovascular disease is the single most important cause of morbidity and mortality in this patient population...
  2. ncbi Autophagy in liver diseases
    Pierre Emmanuel Rautou
    Service d Hepatologie, Hopital Beaujon, Assistance Publique Hopitaux de Paris, Clichy, France
    J Hepatol 53:1123-34. 2010
    ..This decrease in autophagy contributes to the formation of Mallory-Denk bodies and to liver cell death. Hepatic autophagy is defective in the liver in obesity and its upregulation improves insulin sensitivity...
  3. ncbi Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008
    Zobair M Younossi
    Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, Virginia, USA
    Clin Gastroenterol Hepatol 9:524-530.e1; quiz e60. 2011
    Chronic liver diseases (CLDs) are major causes of morbidity and mortality worldwide. We assessed changes in the prevalence of different types of CLD in the United States.
  4. ncbi MiR-122 in hepatic function and liver diseases
    Jun Hu
    CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences CAS, Beijing 100101, China
    Protein Cell 3:364-71. 2012
    ..pathways in hepatocytes, plays a central role in diverse aspects of hepatic function and in the progress of liver diseases. This liver-enriched transcription factors-regulated miRNA promotes differentiation of hepatocytes and ..
  5. ncbi Adipokines in liver diseases
    Fabio Marra
    Department of Internal Medicine, University of Florence, Florence, Italy
    Hepatology 50:957-69. 2009
    ..secreted by expanded adipose tissue and their pathogenic role is pivotal in consideration of the alarming increase in the prevalence of obesity and of the detrimental role that this condition exerts on the course of liver diseases.
  6. ncbi Inflammatory pathways in liver homeostasis and liver injury
    Frank Tacke
    Medical Clinic III, RWTH University Hospital Aachen, Pauwelsstrasse 30, 52074, Aachen, Germany
    Clin Rev Allergy Immunol 36:4-12. 2009
    ....
  7. ncbi IFATS collection: in vivo therapeutic potential of human adipose tissue mesenchymal stem cells after transplantation into mice with liver injury
    Agnieszka Banas
    Section for Studies on Metastasis, National Cancer Center Research Institute, Tokyo, Japan
    Stem Cells 26:2705-12. 2008
    ..in the adult human body, represent an attractive tool for the establishment of a stem cell-based therapy for liver diseases. Recently, the therapeutic potential and immunomodulatory activity of MSCs have been revealed...
  8. ncbi First identification of the hepatotoxic microcystins in the serum of a chronically exposed human population together with indication of hepatocellular damage
    Jun Chen
    Donghu Experimental Station of Lake Ecosystems, State Key Laboratory of Freshwater Ecology and Biotechnology of China, Institute of Hydrobiology, Chinese Academy of Sciences, P R China
    Toxicol Sci 108:81-9. 2009
    ..The results also demonstrate a risk of health effects from chronic exposure to MCs at least for populations with high levels of exposure, like these fishermen...
  9. ncbi Acetaminophen-induced hepatotoxicity
    Laura P James
    Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
    Drug Metab Dispos 31:1499-506. 2003
    ..Other cytokines, such as IL-10, macrophage inhibitory protein-2 (MIP-2), and monocyte chemoattractant protein-1 (MCP-1), appear to be involved in hepatocyte repair and the regulation of proinflammatory cytokines...
  10. ncbi Drug-induced hepatotoxicity
    William M Lee
    Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390 9151, USA
    N Engl J Med 349:474-85. 2003
  11. ncbi Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular
    Tomoaki Ichikawa
    Department of Radiology, University of Yamanashi, School of Medicine, Yamanashi, Japan
    Invest Radiol 45:133-41. 2010
    ....
  12. ncbi Present status and perspectives of cell-based therapies for liver diseases
    Andreas Nussler
    Fresenius Biotech Bad Homburg, Division of Cell Therapy, Bad Homburg, Germany
    J Hepatol 45:144-59. 2006
    ..This paper aims to summarise the present status of cell based therapies for liver diseases and to identify areas of future preclinical and clinical research.
  13. pmc Th17 cells and their associated cytokines in liver diseases
    Fouad Lafdil
    Section on Liver Biology, Laboratory of Physiologic Studies, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, USA
    Cell Mol Immunol 7:250-4. 2010
    ..Recent studies show that the frequency of IL-17(+) cells is significantly elevated in a variety of chronic liver diseases including alcoholic liver disease, viral hepatitis and hepatocellular carcinoma...
  14. pmc Signal transducer and activator of transcription 3 in liver diseases: a novel therapeutic target
    Hua Wang
    Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20892, USA
    Int J Biol Sci 7:536-50. 2011
    ..STAT3 activation is detected virtually in all rodent models of liver injury and in human liver diseases. In this review, we highlight recent advances of STAT3 signaling in liver injury, steatosis, inflammation, ..
  15. ncbi Herbal medicine in the treatment of liver diseases
    F Stickel
    Institute of Clinical Pharmacology, University of Berne, Murtenstrasse 35, CH 3010 Berne, Switzerland
    Dig Liver Dis 39:293-304. 2007
    ..and pharmacovigilance regarding herbal products are still incomplete and clearcut proof of their efficacy in liver diseases is sparse...
  16. pmc Laparoscopic liver resections: a feasibility study in 30 patients
    D Cherqui
    Departments of General and Digestive Surgery and Anesthesiology, H opital Henri Mondor Université Paris XII, Creteil, France
    Ann Surg 232:753-62. 2000
    ..To assess the feasibility and safety of laparoscopic liver resections...
  17. ncbi Increased toxin-induced liver injury and fibrosis in interleukin-6-deficient mice
    K Kovalovich
    Department of Genetics, University of Pennsylvania Medical School, Philadelphia, PA 19104, USA
    Hepatology 31:149-59. 2000
    ..These data provide evidence for an important role for IL-6 in reducing CCl(4)-induced acute and chronic liver injury and fibrosis...
  18. pmc Hypoxia and hypoxia inducible factors: diverse roles in liver diseases
    Bharath Nath
    Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA
    Hepatology 55:622-33. 2012
    ..review investigations that demonstrate a role for HIFs in the development of liver fibrosis, activation of innate immune pathways, hepatocellular carcinoma, as well as other liver diseases in both human disease as well as murine models.
  19. pmc Acute renal dysfunction in liver diseases
    Alex P Betrosian
    Third Department of Critical Care, Athens University, Evgenidion Hospital, Papadiamantopoulou 20, Athens 11528, Greece
    World J Gastroenterol 13:5552-9. 2007
    Renal dysfunction is common in liver diseases, either as part of multiorgan involvement in acute illness or secondary to advanced liver disease. The presence of renal impairment in both groups is a poor prognostic indicator...
  20. ncbi Inflammasomes in liver diseases
    Gyongyi Szabo
    Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605 USA
    J Hepatol 57:642-54. 2012
    Inflammation is a common element in the pathogenesis of most chronic liver diseases that lead to fibrosis and cirrhosis...
  21. ncbi Animal models of chronic liver diseases
    Yan Liu
    Department of Medicine II, Section Molecular Hepatology Alcohol Associated Diseases, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
    Am J Physiol Gastrointest Liver Physiol 304:G449-68. 2013
    Chronic liver diseases are frequent and potentially life threatening for humans. The underlying etiologies are diverse, ranging from viral infections, autoimmune disorders, and intoxications (including alcohol abuse) to imbalanced diets...
  22. pmc Stem cells in liver diseases and cancer: recent advances on the path to new therapies
    C Bart Rountree
    Department of Pediatrics and Pharmacology, Penn State College of Medicine, Hershey, PA 17033, USA
    Hepatology 55:298-306. 2012
    Stem cells have potential for therapy of liver diseases, but may also be involved in the formation of liver cancer. Recently, the American Association for the Study of Liver Diseases Henry M...
  23. pmc Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study
    Hyeon Chang Kim
    Department of Preventive Medicine and Public Health, Yonsei University College of Medicine, 134 Shinchon dong, Seodaemun gu, Seoul 120 752, Republic of Korea
    BMJ 328:983. 2004
    ..To examine the relation between the normal range of serum aminotransferase concentration and mortality from liver disease...
  24. ncbi Recent advances in natural products from plants for treatment of liver diseases
    Aihua Zhang
    National TCM Key Lab of Serum Pharmacochemistry, Key Lab of Chinmedomics, Key Pharmacometabolomics Platform of Chinese Medicines, Heilongjiang University of Chinese Medicine, Heping Road 24, Harbin 150040, China
    Eur J Med Chem 63:570-7. 2013
    ..in vegetables, fruits, plant extracts, herbs, insects, and animals, have been traditionally used for treating liver diseases. They are chemical compounds that usually have biological activities for use in drug discovery and design...
  25. pmc Toll-like receptors as targets in chronic liver diseases
    A Mencin
    Columbia University, College of Physicians and Surgeons, New York, NY, USA
    Gut 58:704-20. 2009
    ..Accordingly, TLR-mediated signals have been implicated in a number of chronic liver diseases. Here, we will summarise recent findings on the role TLRs and TLR ligands in the pathophysiology of liver ..
  26. ncbi Modulation of TGF-beta signaling during progression of chronic liver diseases
    Koichi Matsuzaki
    Department of Gastroenterology and Hepatology, Kansai Medical University, 10 15 Fumizonocho, Moriguchi, Osaka, 570 8507, Japan
    Front Biosci (Landmark Ed) 14:2923-34. 2009
    ..During progression of chronic liver diseases, hepatic epithelial hepatocytes undergo transition from the tumor-suppressive pSmad3C pathway to the ..
  27. ncbi Analysis of regulatory T cells and IgG4-positive plasma cells among patients of IgG4-related sclerosing cholangitis and autoimmune liver diseases
    Masanori Koyabu
    Division of Gastroenterology and Hepatology, The Third Department of Internal Medicine, Kansai Medical University, 10 15 Fumizono, Moriguchi, Osaka, 570 8507, Japan
    J Gastroenterol 45:732-41. 2010
    ..However, the role of IgG4 in the development of IgG4-related SC (IgG4-SC) remains unclear. To clarify the role of IgG4 in IgG4-SC, we have performed an immunohistochemical analysis of the bile duct...
  28. ncbi High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases
    Bing Fang Chen
    School of Medicine, Fu Jen Catholic University, Taipei, Taiwan
    Gastroenterology 130:1153-68. 2006
    ..The interactions among pre-S deletion, precore (PC) mutation, and basal core promoter (BCP) mutation in various stages of chronic hepatitis B virus (HBV) infection remain unclear and were thus investigated in this study...
  29. ncbi Glutathione in liver diseases and hepatotoxicity
    Liyun Yuan
    Internal Medicine, University of Southern California, USA
    Mol Aspects Med 30:29-41. 2009
    ..e. TNF-alpha). These processes have been implicated in the pathogenesis of many liver diseases.
  30. pmc Mutations in PRKCSH cause isolated autosomal dominant polycystic liver disease
    Airong Li
    Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06519, USA
    Am J Hum Genet 72:691-703. 2003
    ..In light of the focal nature of liver cysts in ADPLD, the apparent loss-of-function mutations in PRKCSH, and the two-hit mechanism operational in dominant polycystic kidney disease, ADPLD may also occur by a two-hit mechanism...
  31. ncbi Mechanisms of disease: mechanisms and clinical implications of cholestasis in sepsis
    Andreas Geier
    Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Aachen University, Germany
    Nat Clin Pract Gastroenterol Hepatol 3:574-85. 2006
    ..Patients with progressive sclerosing cholangitis should be considered for orthotopic liver transplantation...
  32. ncbi Digestive and liver diseases statistics, 2004
    Mark W Russo
    Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27599 7555, USA
    Gastroenterology 126:1448-53. 2004
    Digestive and liver diseases are associated with substantial morbidity and mortality in the United States...
  33. ncbi Diffusion-weighted MR imaging of the liver
    Bachir Taouli
    Department of Radiology, New York University Medical Center, New York, NY, USA
    Radiology 254:47-66. 2010
    ..Also, limitations, mainly image quality and reproducibility of diffusion parameters, and future directions of liver DW MR imaging will be discussed...
  34. ncbi Radiation-induced liver disease after three-dimensional conformal radiotherapy for patients with hepatocellular carcinoma: dosimetric analysis and implication
    Jason Chia Hsien Cheng
    Department of Radiation Oncology, Koo Foundation Sun Yat Sen Cancer Center, No 125 Lih Der Road, Pei tou District, Taipei 112, Taiwan
    Int J Radiat Oncol Biol Phys 54:156-62. 2002
    ....
  35. ncbi NF-kappaB signaling, liver disease and hepatoprotective agents
    B Sun
    Liver Transplantation Center of the First Affiliated Hospital and Cancer Center, Nanjing Medical University, Nanjing, Jiangsu Province, PR China
    Oncogene 27:6228-44. 2008
    The NF-kappaB signaling pathway has particular relevance to several liver diseases including hepatitis (liver infection by Helicobacter, viral hepatitis induced by HBV and HCV), liver fibrosis and cirrhosis and hepatocellular carcinoma...
  36. pmc Role of IL-17 and Th17 cells in liver diseases
    Linda Hammerich
    Department of Medicine III, RWTH University Hospital Aachen, Pauwelsstrase 30, 52074 Aachen, Germany
    Clin Dev Immunol 2011:345803. 2011
    ..Indeed, initial studies in humans revealed activated Th17 cells and Th17-related cytokines in various liver diseases. However, functional experiments in mouse models are not fully conclusive at present, and the pathogenic ..
  37. ncbi The burden of gastrointestinal and liver diseases, 2006
    Nicholas J Shaheen
    Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Am J Gastroenterol 101:2128-38. 2006
    Digestive and liver diseases are a source of significant morbidity, mortality, and health-care costs for the U.S. population. An annual report of the toll of these diseases could be helpful to clinicians, policymakers, and researchers.
  38. ncbi Hypervascular liver masses on contrast-enhanced ultrasound: the importance of washout
    Deepak Bhayana
    Department of Medical Imaging, Toronto General Hospital, University of Toronto, 585 University Ave, Toronto, ON M5G 2N2, Canada
    AJR Am J Roentgenol 194:977-83. 2010
    ..The objective of our study was to determine the role of negative enhancement (washout), its presence and timing, in the differential diagnosis of hypervascular liver masses on contrast-enhanced ultrasound...
  39. pmc Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program
    Larry A Allen
    Division of Cardiology, University of Colorado Denver, Aurora, CO, USA
    Eur J Heart Fail 11:170-7. 2009
    ..The prevalence and importance of liver function test (LFT) abnormalities in a large contemporary cohort of heart failure patients have not been systematically evaluated...
  40. ncbi Vitamin E treatment in pediatric obesity-related liver disease: a randomized study
    Pietro Vajro
    Department of Pediatrics, University of Naples Federico II, Italy
    J Pediatr Gastroenterol Nutr 38:48-55. 2004
    ..The authors compared the effect of vitamin E and weight loss on transaminase values and on ultrasonographic bright liver in a controlled group of children with obesity-related liver dysfunction...
  41. ncbi Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors
    Kim M Olthoff
    Department of Surgery, University of Pennsylvania, Philadelphia, PA 19104, USA
    Liver Transpl 16:943-9. 2010
    ..This definition can be used as an endpoint in translational studies aiming to identify mechanistic pathways leading to a subgroup of liver grafts with clinical expression of suboptimal function...
  42. ncbi Genome-wide association studies and genetic risk assessment of liver diseases
    Marcin Krawczyk
    Department of Medicine II, Saarland University Hospital, Saarland University, 66421 Homburg, Germany
    Nat Rev Gastroenterol Hepatol 7:669-81. 2010
    Genetic tests can help clinicians to diagnose rare monogenic liver diseases. For most common liver diseases, however, multiple gene variants that have small to moderate individual phenotypic effects contribute to the overall risk of ..
  43. ncbi Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study
    Maria Stepanova
    Center for Liver Diseases at Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042, USA
    Gut 59:1410-5. 2010
    ..Chronic liver disease (CLD) is a major cause of mortality and morbidity worldwide. The aim of this study was to assess the overall and liver-related mortality and their predictors in patients with CLD using population data...
  44. ncbi Secondary, somatic mutations might promote cyst formation in patients with autosomal dominant polycystic liver disease
    Manoe J Janssen
    Department of Gastroenterology and Hepatology, Institute for Genetic and Metabolic Disease, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Gastroenterology 141:2056-2063.e2. 2011
    ..We investigated whether mutations in cyst epithelial cells and corresponding loss of the PRKCSH gene product (hepatocystin) contributed to cyst development...
  45. ncbi From Mallory to Mallory-Denk bodies: what, how and why?
    Kurt Zatloukal
    Institute of Pathology, Medical University of Graz, Auenbruggerplatz 25, A 8036 Graz, Austria
    Exp Cell Res 313:2033-49. 2007
    ..These inclusions became known as Mallory bodies (MBs) and have since been associated with a variety of other liver diseases including non-alcoholic fatty liver disease...
  46. ncbi Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease
    Gustav Paumgartner
    Department of Medicine II, Klinikum Grosshadern, Marchioninistrasse15, University of Munich, 81377 Munich, Germany
    Clin Liver Dis 8:67-81, vi. 2004
    Ursodeoxycholic acid (UDCA) is widely used for the treatment of cholestatic liver diseases. Multiple mechanisms of action of UDCA have been described aiming at one or more of the pathogenetic processes of cholestatic liver diseases: (1) ..
  47. ncbi Management of hepatic vascular diseases
    Aurelie Plessier
    Pôle des Maladies de l Appareil Digestif, Service d Hepatologie, Centre de Référence des Maladies Vasculaires du Foie, Hopital Beaujon, AP HP, Clichy, France
    J Hepatol 56:S25-38. 2012
    ..Anticoagulation should be considered. (vi) Nodular regenerative hyperplasia is induced by the uneven perfusion due to obstructed sinusoids, or portal or hepatic venules. It causes pure portal hypertension...
  48. ncbi Sulforaphane attenuates hepatic fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-β/Smad signaling
    Chang Joo Oh
    Department of Internal Medicine, Research Institute of Aging and Metabolism, WCU Program, Kyungpook National University School of Medicine, Daegu 700 721, Republic of Korea
    Free Radic Biol Med 52:671-82. 2012
    ..Collectively, these results show that SFN elicits an antifibrotic effect on hepatic fibrosis through Nrf2-mediated inhibition of the TGF-β/Smad signaling and subsequent suppression of HSC activation and fibrogenic gene expression...
  49. pmc Limitations of the MELD score in predicting mortality or need for removal from waiting list in patients awaiting liver transplantation
    Daniel Gotthardt
    Department of Internal Medicine IV, University Hospital of Heidelberg, Heidelberg, Germany
    BMC Gastroenterol 9:72. 2009
    ..The relative shortage of organ donors renders the allocation algorithms of organs essential. The optimal strategy based on scoring systems and/or waiting time is still under debate...
  50. ncbi Carbohydrate antigen 19-9 is extremely elevated in polycystic liver disease
    Esmé Waanders
    Department of Gastroenterology and Hepatology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    Liver Int 29:1389-95. 2009
    ..We examined the value of CA19-9 measurement in polycystic livers after observing high CA19-9 cyst fluid levels in a benign polycystic liver case...
  51. ncbi Mesenchymal stem cells showed the highest potential for the regeneration of injured liver tissue compared with other subpopulations of the bone marrow
    Kyung Ah Cho
    Department of Microbiology, Ewha Womans University College of Medicine, Ewha Medical Research Center, Seoul, Republic of Korea
    Cell Biol Int 33:772-7. 2009
    ....
  52. pmc Emerging role of microRNAs in liver diseases
    Shashi Bala
    Department of Medicine, University of Massachusetts Medical School, LRB 215, Worcester, MA 01605, USA
    World J Gastroenterol 15:5633-40. 2009
    ..Recent studies have shown the involvement of microRNAs in liver diseases caused by various factors, such as Hepatitis C, Hepatitis B, metabolic disorders, and by drug abuse...
  53. ncbi Diabetes and nonalcoholic Fatty liver disease: a pathogenic duo
    K H Williams
    Sydney Medical School and the Bosch Institute, The University of Sydney, Sydney, New South Wales 2006, Australia
    Endocr Rev 34:84-129. 2013
    ..Emerging technology to help screen noninvasively for differing pathological forms of NAFLD and the potential role of preventive and therapeutic approaches for NAFLD in the setting of diabetes are also examined...
  54. ncbi Nuclear receptors as new perspective for the management of liver diseases
    Michael Trauner
    Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Austria
    Gastroenterology 140:1120-1125.e1-12. 2011
    ..Therefore, NRs are key for understanding the pathogenesis and pathophysiology of a wide range of hepatic disorders. Finally, targeting NRs and their alterations offers exciting new perspectives for the treatment of liver diseases.
  55. pmc Hedgehog signaling in cholangiocytes
    Alessia Omenetti
    Division of Gastroenterology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Curr Opin Gastroenterol 27:268-75. 2011
    ..Because this has potential implications for liver repair, this review will summarize current knowledge about Hh signaling and cholangiocytes...
  56. ncbi Diffusion-weighted imaging of the liver: comparison of navigator triggered and breathhold acquisitions
    Bachir Taouli
    NYU Medical Center, Department of Radiology, New York, NY, USA
    J Magn Reson Imaging 30:561-8. 2009
    ..To compare a free breathing navigator triggered single shot echoplanar imaging (SS EPI) diffusion-weighted imaging (DWI) sequence with prospective acquisition correction (PACE) with a breathhold (BH) DWI sequence for liver imaging...
  57. ncbi Contrast enhanced ultrasound should be the initial radiological investigation to characterise focal liver lesions
    C Beaton
    Department of Surgery, University Hospital Wales, Heath Park, Cardiff CF14 4XW, UK
    Eur J Surg Oncol 36:43-6. 2010
    ..This study aims to determine how effective CEUS is at characterising focal liver lesions and to establish its role in the diagnostic algorithm...
  58. ncbi Cyclooxygenase-2 expression in chronic liver diseases and hepatocellular carcinoma: an immunohistochemical study
    Lydia Giannitrapani
    Department of Clinical Medicine and Emerging Pathologies, University of Palermo, Italy
    Ann N Y Acad Sci 1155:293-9. 2009
    ..Using immunohistochemistry, we studied COX-2 expression in different chronic liver diseases (CLD) including nonalcoholic steatohepatitis (NASH), chronic hepatitis (CH), liver cirrhosis (LC), and HCC in ..
  59. pmc Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease
    Marie C Hogan
    Division of Nephrology and Hypertension, Department of Biomedical STatistics and Informatics, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    J Am Soc Nephrol 21:1052-61. 2010
    ..In summary, octreotide slowed the progressive increase in liver volume and total kidney volume, improved health perception among patients with PLD, and had an acceptable side effect profile...
  60. ncbi Respiratory gated diffusion-weighted imaging of the liver: value of apparent diffusion coefficient measurements in the differentiation between most commonly encountered benign and malignant focal liver lesions
    Sofia Gourtsoyianni
    Department of Radiology, University Hospital of Heraklion, 71110 Stavrakia, Heraklion Crete, Greece
    Eur Radiol 18:486-92. 2008
    ..0001). Respiratory gated diffusion-weighted imaging in the liver is technically feasible. Apparent diffusion coefficient measurements can be useful in differentiating malignant from benign focal liver lesions...
  61. ncbi Bile ductular cells undergoing cellular senescence increase in chronic liver diseases along with fibrous progression
    Motoko Sasaki
    Department of Human Pathology, Kanazawa University Graduate School of Medicine, Kanazawa 920 8640, Japan
    Am J Clin Pathol 133:212-23. 2010
    We investigated the pathologic significance of ductular reactions in chronic liver diseases with respect to cellular senescence...
  62. pmc Cell therapies for liver diseases
    Yue Yu
    Division of Experimental Surgery, Department of Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Liver Transpl 18:9-21. 2012
    ..liver support and hepatocyte transplantation, have emerged as potential treatments for a variety of liver diseases. Acute liver failure, acute-on-chronic liver failure, and inherited metabolic liver diseases are examples of ..
  63. pmc The contribution of endoplasmic reticulum stress to liver diseases
    Lily Dara
    University of Southern California Research Center for Liver Diseases, Los Angeles, CA, USA
    Hepatology 53:1752-63. 2011
    ..Over the past 2 decades, the contribution of ER stress to various forms of liver diseases has been examined...
  64. pmc The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda
    Ponsiano Ocama
    Infectious Diseases Institute, Kampala, Uganda
    Afr Health Sci 8:8-12. 2008
    b>Liver diseases are common in patients with HIV due to viral hepatitis B and C co-infections, opportunistic infections or malignancies, antiretroviral drugs and drugs for opportunistic infections.
  65. ncbi Liver diffusion-weighted MR imaging: the tower of Babel?
    Boris Guiu
    Eur Radiol 21:463-7. 2011
    ..Here, we review the main principles of DWI of the liver, the limits of the ADC, and the exciting capabilities of multi-parametric DWI. We also insisted on the need for a common language for DWI of the liver...
  66. ncbi Bile leak test by indocyanine green fluorescence images after hepatectomy
    Takanori Sakaguchi
    Second Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan
    Am J Surg 200:e19-23. 2010
    ..The new bile leak test by ICG fluorography is useful to prevent postoperative bile leak...
  67. ncbi The role of Smad3 in mediating mouse hepatic stellate cell activation
    B Schnabl
    Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    Hepatology 34:89-100. 2001
    ....
  68. ncbi Hemostatic abnormalities and liver diseases
    Hideo Wada
    Departments of Molecular and Laboratory Medicine, Mie University Graduate School of Medicine, Tsu City, Japan
    Semin Thromb Hemost 34:772-8. 2008
    ..Mammen greatly contributed to the understanding of the relationship between hemostatic abnormalities and liver diseases. The physiology of the hemostatic system is closely linked to liver function because the liver parenchymal ..
  69. ncbi A comparison of fibrosis progression in chronic liver diseases
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, et UPRESA 8067 CNRS, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
    J Hepatol 38:257-65. 2003
    No study has compared the liver fibrosis progression rates among chronic liver diseases and the risk factors in order to better organize screening strategies.
  70. ncbi Role of nuclear factor kappaB in liver health and disease
    Stuart M Robinson
    Cell Signalling Group, Institute of Cellular Medicine, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, UK
    Clin Sci (Lond) 118:691-705. 2010
    ..We explore the weaknesses of the experimental approaches to date and suggest that further work is needed to investigate in detail the discreet functions of each of the Rel subunits in liver physiology and disease...
  71. ncbi Evolving concepts in cell therapy of liver disease and current clinical perspectives
    Maurizio Muraca
    Department of Laboratory Medicine, IRCCS Ospedale Bambino Gesù, Rome, Italy
    Dig Liver Dis 43:180-7. 2011
    ..experimental results encouraged pilot clinical trials using hepatocytes transplantation to treat a variety of liver diseases. More recently, the discovery of liver stem/progenitor cells further fueled the interest in the field...
  72. ncbi Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging
    Utaroh Motosugi
    Department of Radiology, University of Yamanashi, Chuo shi, Yamanashi, Japan
    Radiology 256:151-8. 2010
    ....
  73. ncbi Association between duplex Doppler sonographic flow pattern in right hepatic vein and various liver diseases
    A von Herbay
    Department of Gastroenterology, Hepatology and Infectious Diseases, , Moorenstrasse 5, , Germany
    J Clin Ultrasound 29:25-30. 2001
    ..to evaluate the association between the Doppler sonographic waveforms in the right hepatic vein and various liver diseases. METHODS: We performed Doppler sonography of the right hepatic vein in 225 individuals (189 patients with ..
  74. ncbi Immunohistochemical evidence for hepatic progenitor cells in liver diseases
    Jianyou Tan
    Department of Pathology, New York University Medical Center, New York, NY 10016, USA
    Liver 22:365-73. 2002
    Proliferative bile ductular reactions occur in a variety of liver diseases in humans...
  75. ncbi Clinical profile of autosomal dominant polycystic liver disease
    Qi Qian
    Division of Nephrology, Mayo Clinic, Rochester, MN, USA
    Hepatology 37:164-71. 2003
    ..In conclusion, isolated ADPLD is underdiagnosed and genetically distinct from polycystic liver disease associated with ADPKD but with similar pathogenesis, manifestations, and management...
  76. ncbi Perioperative management of hepatic resection toward zero mortality and morbidity: analysis of 793 consecutive cases in a single institution
    Toshiya Kamiyama
    Department of General Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan
    J Am Coll Surg 211:443-9. 2010
    ..The mortality rates associated with hepatectomy are still not zero. Our aim was to define the risk factors for complications and to evaluate our perioperative management...
  77. ncbi Sphingolipid signalling and liver diseases
    Montserrat Mari
    Liver Unit and Centro de Investigaciones Biomédicas Esther Koplowitz, IMDiM, Hospital Clinic i Provincial, CIBER HEPAD, Instituto Salud Carlos III, IDIBAPS, Barcelona, Spain
    Liver Int 27:440-50. 2007
    ..SLs in stress and death ligand-induced hepatocellular death, which contributes to the progression of several liver diseases including steatohepatitis, ischaemia-reperfusion liver injury or hepatocarcinogenesis...
  78. ncbi Soluble CD163 in patients with liver diseases: very high levels of soluble CD163 in patients with fulminant hepatic failure
    Atsushi Hiraoka
    The Third Department of Internal Medicine, Ehime University School of Medicine, Ehime 791 0295, Japan
    J Gastroenterol 40:52-6. 2005
    The levels of several cytokines and chemokines are elevated in various liver diseases, especially in fulminant hepatic failure (FHF). Activated macrophages may have a role in the production of these immune modulators...
  79. ncbi Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease
    Dominique Debray
    Pediatric Hepatology, APHP CHU Necker Enfants Malades and INSERM, UMR S 938, Centre de Recherche Saint Antoine, Paris, France
    J Cyst Fibros 10:S29-36. 2011
    ..Deterioration of pulmonary function is an important consideration for liver transplantation, particularly in children with hepatic dysfunction or advanced portal hypertension...
  80. ncbi Progressive histological damage in liver allografts following pediatric liver transplantation
    Helen M Evans
    Liver Unit, Birmingham Children s Hospital, Birmingham, United Kingdom
    Hepatology 43:1109-17. 2006
    ..The cause of chronic hepatitis in transplanted allografts is uncertain but may be immune mediated, representing a hepatitic form of chronic rejection...
  81. ncbi Lipopolysaccharides in liver injury: molecular mechanisms of Kupffer cell activation
    Grace L Su
    Medical Service, Department of Veterans Affairs Medical Center, University of Michigan, Ann Arbor 48109, USA
    Am J Physiol Gastrointest Liver Physiol 283:G256-65. 2002
    ..Signaling of lipopolysaccharide through CD14 is mediated by the downstream receptor Toll-like receptor 4 and results in activation of Kupffer cells. The role played by these molecules in liver injury will be examined...
  82. ncbi Characterization of liver lesions with mangafodipir trisodium-enhanced MR imaging: multicenter study comparing MR and dual-phase spiral CT
    Matthijs Oudkerk
    Dept of Radiology, Daniel den Hoed Cancer Ctr, Univ Hosp Rotterdam, The Netherlands
    Radiology 223:517-24. 2002
    ..To evaluate whether mangafodipir trisodium (Mn-DPDP)-enhanced magnetic resonance (MR) imaging surpasses dual-phase spiral computed tomography (CT) in differentiating focal liver lesions...
  83. ncbi Molecular diagnosis of multistage hepatocarcinogenesis
    Michiie Sakamoto
    Department of Pathology, Keio University, 35 Shinanomachi, Shinjuku ku, Tokyo 160 8582, Japan
    Jpn J Clin Oncol 40:891-6. 2010
    ....
  84. ncbi Liver disease in patients with diabetes mellitus
    Stephen A Harrison
    Department of Hepatology, Brooke Army Medical Center, Fort Sam, Houston, TX, USA
    J Clin Gastroenterol 40:68-76. 2006
    ..The ensuing article will review the relationship between diabetes mellitus and two common liver diseases: chronic hepatitis C and nonalcoholic fatty liver disease...
  85. ncbi The Mallory body: morphological, clinical and experimental studies (Part 1 of a literature survey)
    K Jensen
    Department of Medical Gastroenterology, Hvidovre University Hospital, Denmark
    Hepatology 20:1061-77. 1994
    ..Studies in alcoholic hepatitis strongly suggest a hit-and-run effect of alcohol, whereas other chronic liver diseases show evidence of gradual increase in prevalence of Mallory bodies with severity of hepatic pathology...
  86. ncbi Intestinal failure-associated liver disease: what do we know today?
    Deirdre A Kelly
    The Liver Unit, Birmingham Children s Hospital, NHS Trust, Birmingham, England
    Gastroenterology 130:S70-7. 2006
    ....
  87. ncbi Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States
    Constance E Ruhl
    Social and Scientific Systems Inc, 8758 Georgia Avenue, Silver Spring, MD 20910, USA
    Gastroenterology 128:24-32. 2005
    ....
  88. pmc Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs
    Giuseppe Traversa
    Department of Epidemiology, National Institute of Health, Viale Regina Elena 299, 00161 Rome, Italy
    BMJ 327:18-22. 2003
    ..To estimate the risk of acute hepatotoxicity associated with nimesulide compared with other non-steroidal anti-inflammatory drugs...
  89. ncbi The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule
    Yasuko Iwakiri
    Hepatic Hemodynamic Laboratory, VA Connecticut Healthcare System, West Haven, CT 06516, USA
    Hepatology 43:S121-31. 2006
    The hyperdynamic circulatory syndrome observed in chronic liver diseases is a great example of research that originated from clinical observations and progressed in the last 50 years from the patient to the experimental laboratory...
  90. pmc Improved characterisation of histologically proven liver tumours by contrast enhanced ultrasonography during the portal venous and specific late phase of SHU 508A
    C F Dietrich
    Second Department of Internal Medicine, Caritas Hospital Bad Mergentheim, Germany
    Gut 53:401-5. 2004
    ....
  91. ncbi Cell transplantation in the treatment of liver diseases
    F Smets
    Université Catholique de Louvain et Cliniques Universitaires Saint Luc, Laboratory of Pediatric Hepatology and Cell Therapy, Brussels, Belgium
    Pediatr Transplant 12:6-13. 2008
    ..Ongoing lines of research are discussed, including cell quality, stem cell field, and rejection prevention. Further improvement of the procedure is therefore expected and should lead to broader applications of LCT...
  92. ncbi Liver regeneration
    Leonidas G Koniaris
    Department of Surgery, University of Rochester School of Medicine, Rochester, NY, USA
    J Am Coll Surg 197:634-59. 2003
  93. ncbi Quantitative analysis of elevated serum Golgi protein-73 expression in patients with liver diseases
    YanLi Gu
    Laboratory of Viral Immunology, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510663, China
    Ann Clin Biochem 46:38-43. 2009
    Golgi protein-73 (GP73) is a newly identified candidate serum marker for liver diseases. The utility of this biomarker remains limited, largely due to the lack of quantitative information...
  94. ncbi The 148M allele of the PNPLA3 gene is associated with indices of liver damage early in life
    Stefano Romeo
    Endocrinology and Diabetes, Department of Medical Sciences, University of Cagliari, Cagliari, Italy
    J Hepatol 53:335-8. 2010
    ..In this study we add further insight into the role of PNPLA3 by exploring whether this association begins early in life in obese children or becomes manifest only in adulthood...
  95. pmc A genetic interaction network of five genes for human polycystic kidney and liver diseases defines polycystin-1 as the central determinant of cyst formation
    Sorin V Fedeles
    Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
    Nat Genet 43:639-47. 2011
    ....
  96. ncbi Improved focal liver lesion detection: comparison of single-shot diffusion-weighted echoplanar and single-shot T2 weighted turbo spin echo techniques
    K Coenegrachts
    Department of Radiology, AZ St Jan AV, Bruges, Belgium
    Br J Radiol 80:524-31. 2007
    ..05). This study shows the potential of SS SE-EPI DWI (especially with a b-value of 20 s mm(-2)) as a promising technique for detecting small (<10 mm) focal liver lesions...
  97. ncbi Importance of peroxisome proliferator-activated receptor-gamma in hepatic ischemia/reperfusion injury in mice
    Takahiro Akahori
    Department of Surgery, Nara Medical University, Nara, Japan
    J Hepatol 47:784-92. 2007
    ..However, the precise role of PPARgamma in acute liver injury remains unknown...
  98. ncbi Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree
    Melanie K Seale
    Division of Abdominal Imaging and Intervention, Massachusetts General Hospital, White 270, 55 Fruit St, Boston, MA 02114, USA
    Radiographics 29:1725-48. 2009
    ..In the future, hepatobiliary-specific contrast agents may have wider applications, such as grading of cirrhosis and quantification of liver function...
  99. pmc The incidence and risks of liver biopsy in non-cirrhotic patients: An evaluation of 3806 biopsies
    Jee Fu Huang
    Gut 56:736-7. 2007
  100. ncbi Obesity-associated liver disease
    Giulio Marchesini
    University of Bologna, Via Massarenti, 9, I 40138 Bologna, Italy
    J Clin Endocrinol Metab 93:S74-80. 2008
    ..Accordingly, the worldwide epidemic of obesity is likely to become a relevant source of morbidity and mortality in the general population...
  101. ncbi Characterisation of the liver progenitor cell niche in liver diseases: potential involvement of Wnt and Notch signalling
    Bart Spee
    Department of Morphology and Molecular Pathology, University Hospitals Leuven, Leuven, Belgium
    Gut 59:247-57. 2010
    Hepatic progenitor cells (HPCs) hold a great potential for therapeutic intervention for currently untreatable liver diseases. However, in human diseases molecular mechanisms involved in proliferation and differentiation of HPCs are poorly ..

Research Grants75

  1. Mice Humanized with Hepatocytes and iPS Cells from Patients with Metabolic Diseas
    Stephen C Strom; Fiscal Year: 2010
    ..rats) are particularly poor models for studying liver fibrosis and cirrhosis, common features of many human liver diseases. Humanized mice may offer a platform to both the study and treatment of hepatic fibrosis and cirrhosis...
  2. Pathogenesis and Treatment of Liver Disease in Transaldolase Deficiency
    Andras Perl; Fiscal Year: 2013
    ..Although oxidative stress is implicated in both acute acetaminophen-induced liver failure and chronic liver diseases, cirrhosis and hepatocellular carcinoma (HCC), no common underlying metabolic pathways have been identified...
  3. Impact of the P479L Variant in CPT1A on Infant Mortality in Alaska
    David M Koeller; Fiscal Year: 2011
    ..The results of this study will aid in the development of evidence-based guidelines for the treatment of Alaska Native infants diagnosed with CPT1A deficiency by newborn screening. ..
  4. Hybrid Optical/Doppler Imaging of Ischemia in NEC - a multicenter trial
    David A Benaron; Fiscal Year: 2010
    ..If successful, the health benefit will be large, as it is estimated that treating NEC alone (not including treating its later complications) adds $650 million to the annual health bill. ..
  5. Novel diagnostic and safety biomarkers of liver injury and hepatotoxicity
    Stanislav I Svetlov; Fiscal Year: 2010
    ..data indicating the diagnostic and prognostic value of serum ASS in human patients with several types of liver diseases and hepatic injury...
  6. Iron-Induced Changes in Liver That Predispose to Malignancy
    Harriet C Isom; Fiscal Year: 2010
    ..In many chronic liver diseases that culminate in HCC, excess iron deposition is a common factor...
  7. Functional characters of non-coding RNAs in alcoholic liver injury
    Fanyin Meng; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Project Summary Alcoholic liver diseases (ALD) -- ranging from alcoholic fatty liver to alcohol-induced liver fibrosis and cirrhosis - - account for more than 50% of all chronic liver diseases in ..
  8. Novel SCID rat models for human cell transplantation studies
    Joseph C Ruiz; Fiscal Year: 2010
    ..There is a compelling need for an abundant and accessible supply of animals to screen for new therapeutic agents. Thus, if successful, this project would benefit many goals of public health. ..
  9. Transplacental Arsenic Induced Hepatic Dysfunction and Vascular Disease
    J Christopher States; Fiscal Year: 2010
    ..This project uses a mouse model of fetal arsenic exposure induced vascular disease to investigate effects of fetal arsenic exposure on liver development that likely cause vascular disease by young adulthood. ..
  10. Nanoemulsion-based vaccine for chronic hepatitis B virus
    James R Baker; Fiscal Year: 2010
    ..great value as a commercialized product to reduce the risk and associated financial burden of HBV- associated liver diseases and deaths both in the United States and globally...
  11. Potential Mechanisms of Glucagon-like peptide-1 in Fatty Liver Disease
    Frank A Anania; Fiscal Year: 2010
    ..This proposal meets the goals of the US Public Health Service in treating chronic liver diseases.
  12. Histamine modulation of biliary proliferation and damage
    Heather L Francis; Fiscal Year: 2013
    ..pathways that can be targeted for the development of therapeutic interventions for chronic cholestatic liver diseases. The study introduces the novel concept that HDC may be an important therapeutic target for the management of ..
  13. Androgen Receptor Pathway and Risk of Hepatic Fibrosis in Hepatitis C
    DONNA LORRAINE WHITE; Fiscal Year: 2013
    ..will also extend my NIDDK-sponsored K01 research and training in genetic epidemiology of chronic digestive and liver diseases, and also provide foundational data needed to support an R01 application I plan to submit in K01 Year 5 to ..
  14. Detection of Liver Fibrosis Using IVIM Diffusion and DCE MRI in HCV
    Bachir Taouli; Fiscal Year: 2013
    ..This will be a highly significant progress in liver diseases given the increased burden of HCV in this country, and would benefit a large number of Americans over the next ..
  15. NPC1L1 and Metabolic Diseases
    Liqing Yu; Fiscal Year: 2013
    ..for the prevention and treatment of metabolic diseases such as obesity, type 2 diabetes and nonalcoholic fatty liver diseases. Given that NPC1L1 is the target of ezetimibe, an FDA-approved intestinal cholesterol absorption inhibitor ..
  16. UT GASTROENTEROLOGY / HEPATOLOGY RESEARCH TRAINING PROGRAM
    Ezra Burstein; Fiscal Year: 2013
    ..program is aimed at producing the next generation of scientific leaders focused on understanding digestive and liver diseases. The program involves a variety of disciplines broadly categorized into two main areas: basic scientific ..
  17. Effect of HIV protease inhibitor on alcohol induced ER stress and liver injury.
    Cheng Ji; Fiscal Year: 2013
    ..Understanding of additive/synergistic effects of HIV PIs and alcohol on the ER stress that worsens liver injury will provide better strategies to improve care for HIV-infected patients. ..
  18. Excessive Copper Levels Disrupt Hepatic Nuclear Receptor Function
    Clavia Ruth Wooton-Kee; Fiscal Year: 2011
    ..This research specifically addresses the biological mechanisms relevant to human liver pathology and to Wilson's disease. ..
  19. GROWTH REGULATION OF THE INTRAHEPATIC BILIARY TREE
    GIANFRANCO D ALPINI; Fiscal Year: 2010
    ..Cholangiocytes are the targets of damage during chronic cholestatic liver diseases (cholangiopathies) such as primary biliary cirrhosis, primary sclerosing cholangitis, and cholangiocarcinoma...
  20. Biliary Atresia, Cholestatic Liver Diseases, and Cystic Fibrosis: Indiana Univers
    Jean Pappas Molleston; Fiscal Year: 2013
    ..Aim 1: Contribute to the existing studies in the Biliary Atresia Research Consortium (BARC), the Cholestatic Liver Diseases Research Consortium (CLiC) and Cystic Fibrosis Liver Disease Research Consortium (CFLD), which are merging to ..
  21. Deriving hepatocytes from disease specific iPS to treat metabolic liver disorders
    Namita Roy-Chowdhury; Fiscal Year: 2013
    ..of this project will provide a renewable source of autologous hepatocytes that, after additional modification and scale up, could be translated into cell transplantation-based treatment of CN1 and many other inherited liver diseases.
  22. Sterile Hepatic Inflammation
    Wajahat Zafar Mehal; Fiscal Year: 2012
    ..Currently there are no effective treatments these liver diseases. This is due to the fact that we have a very poor understanding of how liver inflammation and injury start in ..
  23. New pathways regulating bile acid homeostasis and cholestatic liver diseases
    Li Wang; Fiscal Year: 2013
    ..of cytotoxic bile acids, leading to liver injury to bile ducts and hepatocytes, and resulting in cholestatic liver diseases. Although it is well established that nuclear receptors are important transcriptional regulators of bile acid ..
  24. Hepatic Lipase and HCV Infection
    Tianyi Wang; Fiscal Year: 2010
    ..with lower plasma cholesterol levels and the accumulation of fat in livers (steatosis), a state preceding many liver diseases owing to its intimate association with obesity and insulin-resistant diabetes mellitus...
  25. Colorado Center for Childhood Liver Disease Research and Education
    Ronald J Sokol; Fiscal Year: 2013
    Cholestatic liver diseases are among the most important liver disorders that occur in infants and children, leading to devastating morbidity and accounting for over 70% of liver transplants performed during childhood, posing a major ..
  26. Role of sumoylation in alcoholic liver disease
    Maria Lauda Tomasi; Fiscal Year: 2013
    ..The liver, as the primary site of alcohol metabolism, is a major target of injury. The spectrum of Alcoholic Liver Diseases (ALD) includes simple steatosis, alcoholic hepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma...
  27. The Pittsburgh Cholestatic Liver Disease Consortium
    Benjamin L Shneider; Fiscal Year: 2013
    Neonatal cholestatic liver diseases including Alagille syndrome, alpha-1 antitrypsin deficiency, bile acid synthesis defects, biliary atresia, cystic fibrosis, mitochondrial hepatopathies and progressive familial intrahepatic cholestasis,..
  28. Alcohol &Antiretrovirals in HIV Infection, Oxidative Stress and Liver Disease
    Marianna K Baum; Fiscal Year: 2012
    ....
  29. Alcoholic Liver Dysfunction Potentiation by Hyperlipidemia and Cigarette Smoke
    SHANNON MARIE BAILEY; Fiscal Year: 2013
    ..Importantly, new studies report an increasing prevalence and severity of liver diseases from all causes in the US...
  30. MLK3 in metabolic stress signaling
    Anja Jaeschke; Fiscal Year: 2013
    ..The proposed study will increase understanding of the molecular mechanisms by which saturated FFA contribute to the development of NAFLD. This information may suggest novel therapeutic strategies for the prevention of NAFLD. ..
  31. Novel Small Molecules For Acute Liver Failure
    Prakash Narayan; Fiscal Year: 2009
    ..PUBLIC HEALTH RELEVANCE: Acute liver failure remains a significant cause of morbidity and mortality. A small molecule hepatocyte growth factor mimetic that is hepatoprotective and hepatoregenerative is of tremendous clinical benefit. ..
  32. MOLECULAR REGULATION OF ILEAL/RENAL BILE ACID TRANSPORT
    Benjamin L Shneider; Fiscal Year: 2012
    ..These studies will advance our understanding of the regulation of ASBT and provide new ways to understand and treat intestinal and liver diseases.
  33. Molecular Epidemiology of Chronic Liver Diseases
    Manal Hassan; Fiscal Year: 2009
    ..Hashem El-Serag (co-mentor), an expert in HCV-induced chronic liver diseases will supervise the epidemiological and clinical components of hepatitis C virus (HCV) and liver cirrhosis...
  34. Genetic Susceptibility Factors in Porphyria Cutanea Tarda (PCT)
    Karl Anderson; Fiscal Year: 2009
    ..PCT itself causes liver damage, and genetic factors that promote its development may play a role in other liver diseases, such as those induced by hepatitis C and alcohol...
  35. Control of liver autophagy by phosphatidic acid signaling
    GILBERT DIPAOLO; Fiscal Year: 2013
    ..role of macrolipophagy in the control of lipid metabolism and provide the basis for future work testing whether stimulating the PLD1 pathway can be exploited to promote macrolipophagy in human conditions, such as fatty liver diseases.
  36. Developing Novel Serological Biomarkers for Autoimmune Liver Diseases
    Xuhang Li; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Autoimmune liver diseases (AILDs), including autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC), are chronic and incurable immune disorders of the ..
  37. Functional significance of Siglec-6, a novel leptin receptor, in human placental
    Virginia Winn; Fiscal Year: 2013
    ..For the baby, PE can cause growth failure or stillbirth. Those babies that do survive have an increased risk of disorders as adults including diabetes and heart disease. ..
  38. Nrf2 as a Master Regulator in Liver Disease Prevention and Therapy
    Curtis D Klaassen; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Current therapeutic interventions for treating liver diseases are very limited;identification of a therapeutic target is a prerequisite for developing new drugs to treat liver diseases...
  39. Antiviral prophylaxis to prevent perinatal transmission of HBV in Thailand
    GONZAGUE JOSEPH JOURDAIN; Fiscal Year: 2013
    ..and safety of antiviral treatment and this approach is not recommended by the Associations for the Study of Liver Diseases. We hypothesize that tenofovir or lamivudine can decrease HBV viral load in HBV infected pregnant women and ..
  40. Genome-Wide Analysis of RXR-alpha Binding In Mouse Liver Chromatin with ChIP-SEQ
    SAUL JOSEPH KARPEN; Fiscal Year: 2010
    ..With current therapeutic emphases on exploring NR ligands as therapeutics for a variety of liver diseases, these data are critical for finding therapeutic targets, avoiding toxicities, and screening likely candidate ..
  41. A Microfluidic-platform Mini-Liver System for Human Liver Biology Studies
    HONGSEOK M NOH; Fiscal Year: 2010
    ..Epidemiological studies have linked some types of infectious agents and alcohol consumption with liver diseases and liver cancer;however, attempts to fully characterize many of these diseases in humans have been hampered ..
  42. USC Research Center for Liver Disease
    Neil Kaplowitz; Fiscal Year: 2013
    DESCRIPTION, OVERALL (provided by applicant): The University of Southern California Research Center for Liver Diseases, funded since 1995, has the goal of fostering and facilitating interdisciplinary research in liver and digestive ..
  43. PERINATAL MECHANISMS OF DETOXIFICATION
    Eric F Johnson; Fiscal Year: 2013
    ..Additionally, we will address how genetic deficiencies of this capacity affect susceptibility to hypertension due to renal and liver dysfunction. ..
  44. Regulation of HBV Replication by the Immune System
    Luca G Guidotti; Fiscal Year: 2012
    ..Public Health Relevance: Hepatitis B virus (HBV) cause acute and chronic liver diseases. Chronic HBV infection is associated with varying degrees of liver damage, and it often progresses to the ..
  45. Role of Hepatitis B virus X protein in HBV replication
    Michael J Bouchard; Fiscal Year: 2011
    ..to effects identified in mRNA and miRNA microarray profile databases of liver biopsies from HBV-associated liver diseases to compare observations in cultured hepatocytes to observations in HBV-associated liver diseases in humans...
  46. CYTOSKELETAL REGULATION OF VESICLE TRANSPORT IN LIVER
    MARK A MC NIVEN; Fiscal Year: 2013
    ..Further, their disruption can lead to a variety of prevalent liver diseases. Here we focus on the vesicle-based machinery utilized by the hepatocyte at the plasma membrane (PM) and trans-..
  47. Dissecting the Role of Unfolded Protein Response in Alcoholic Liver Disease
    Ling Qi; Fiscal Year: 2013
    ..This study, if successful, may delineate key signaling pathways in alcoholic liver disease and identify new targets for preventing and treating alcoholic liver diseases as well as other forms of liver diseases.
  48. Regulation of Hepatic Metabolic Function by Parenteral Nutrition
    Douglas G Burrin; Fiscal Year: 2013
    ..Infants given total parenteral nutrition (TPN) have increased risk for metabolic liver diseases. Our preliminary studies in premature piglets show that TPN enriched with phytosterols and n-6 fatty acids (FA)..
  49. Transgenic mouse models of HCV infection and replication
    Jieyun Jiang; Fiscal Year: 2012
    ..HCV infection is a major risk factor for HCC development. HCV- associated end-stage of liver diseases is the leading indication for liver transplantation...
  50. Age Effects on Liver Inflammation and Injury
    Alex B Lentsch; Fiscal Year: 2013
    ....
  51. MOLECULAR BIOLOGY OF BILE ACID SYNTHESIS
    JOHN CHIANG; Fiscal Year: 2009
    ..Drugs targeting to nuclear receptor and signaling pathways, and miRNA antagomirs may be developed for treating metabolic liver diseases.
  52. Control of cAMP Mediated Glucagon Response by Bile Acids
    Norman H Lee; Fiscal Year: 2011
    ..and add new insight to the understanding of the attenuation of glucagon responsiveness in cholestatic liver diseases. These studies will define molecular mechanisms regulating both PKC and glucagon receptor activation by bile ..
  53. Role for tissue-type plasminogen activator in suppression of hepatic fibrosis
    Liang I Kang; Fiscal Year: 2013
    ..by applicant): Liver fibrosis (scarring) develops as a consequence of a variety of chronic inflammatory liver diseases, and if untreated, will progress into cirrhosis and liver failure...
  54. Hepatocyte Clock and Alcoholic Fatty Liver Injury
    SHANNON MARIE BAILEY; Fiscal Year: 2011
    ..New studies report an increasing prevalence and severity of liver diseases from all causes in the United States...
  55. Role of Uhrf1 in Liver Development, Regeneration and Carciogenesis
    Chinweike Ukomadu; Fiscal Year: 2013
    ..that can aid in the development of chemotherapeutic agents for use in management of patients with chronic liver diseases including HCC...
  56. MOLECULAR BIOLOGY OF BILE ACID SYNTHESIS
    John Y L Chiang; Fiscal Year: 2013
    ..Drugs targeting to nuclear receptor and signaling pathways, and miRNA antagomirs may be developed for treating metabolic liver diseases.
  57. Novel prognostic microRNA biomarkers for primary sclerosing cholangitis
    Kris Kowdley; Fiscal Year: 2013
    ..studies have shown that levels of many circulating serum miRNA are elevated in patients with a variety of liver diseases and pathologies including HCC, HBV and liver cirrhosis...
  58. Liver Inflammation and Injury: Molecular Mechanisms
    Mario Chojkier; Fiscal Year: 2013
    ..It provides an opportunity to control liver inflammation and injury in patients with acute and chronic liver diseases as well as potential therapeutic strategies for the prevention and treatment of liver inflammation and injury...
  59. OUTER MEMBRANE PROTEINS OF PATHOGENIC LEPTOSPIRA SPECIES
    David A Haake; Fiscal Year: 2013
    ..We will develop outer membrane protein-based vaccines that prevent acquisition of renal infection by reservoir hosts and effectively block shedding of pathogenic leptospires. ..
  60. Functions of MRP2 and MRP3 in Drug Disposition
    James M Gallo; Fiscal Year: 2011
    ..These improvements could potentially allow the drugs to be given by mouth instead of intravenously, and also reduce the side effects that are associated with the way the body disposes of anticancer agents. ..
  61. Dietary Fat in Ethanol-Induced Intestinal Barrier Dysfunction in ALD
    Irina Kirpich; Fiscal Year: 2013
    ..ALD remains one of the leading causes of liver diseases and a major cause of morbidity and mortality in the United States and worldwide...
  62. Degradation of Endoplasmic Reticulum Chaperones by Chaperone-mediated Autophagy
    Roberta Kiffin; Fiscal Year: 2010
    ..human disorders such as neurodegenerative disorders, metabolic diseases such as diabetes and severe liver diseases, among others...
  63. REGULATION OF BILE ACID SYNTHESIS
    JOHN CHIANG; Fiscal Year: 1999
    ..conditions such as hypercholesterolemia, atherosclerosis, cholelithiasis, sterol storage diseases and liver diseases in humans...
  64. MR Spectroscopy to Evaluate Liver Repopulation by Transplanted Hepatocytes
    Chandan Guha; Fiscal Year: 2009
    ..could be an alternative to orthotopic liver transplantation in the treatment of both inherited and acquired liver diseases. However, benefits of this procedure are currently limited by (i) the inability of the transplanted ..
  65. A Novel Therapeutic Approach for Liver Injury
    Xiaoling Qiang; Fiscal Year: 2010
    ..is more clinically relevant) is also equally protective after hepatic I/R injury with or without pre-existing liver diseases such as hepatic injury induced by bile duct ligation (BDL)...
  66. Decoy receptor 3 and liver cirrhosis
    Sunghee Kim; Fiscal Year: 2006
    ..Thus, how to best evaluate and manage the increasing numbers of patients with chronic liver diseases is 1 of the major clinical problems...
  67. Cell Culture System for Hepatitis C Virus Genotype 1a
    Adrian Di Bisceglie; Fiscal Year: 2009
    ..virus (HCV) results in persistent infection in up to 80% of infected individuals and causes a wide spectrum of liver diseases. Liver disease related to chronic HCV infection is now the leading indication for liver transplantation in the ..
  68. Molecular basis of congenital disorders of glycosylation: mechanisms of oligosach
    Smita Mohanty; Fiscal Year: 2010
    ..Thus understanding the molecular basis of function of this complex integral membrane protein is very critical for the treatment or for therapeutic intervention of the above diseases. ..
  69. Naturally Occurring Agent for Alcohol Liver Diseases
    YUE WEI LEE; Fiscal Year: 2003
    ..For a medication development project focusing on alcohol liver diseases, it is essential to understand, at the molecular level, potential alterations in cellular signal transduction ..
  70. Liver innate immunity in drug-induced liver disease
    Zhang Xu Liu; Fiscal Year: 2006
    ..significant commitment to research activities in the area of the liver immune response as it pertains to liver diseases. The K01 Award would enable the candidate to build upon previous research experiences in immunology and gain ..
  71. PILOT STUDY OF PIRFENIDONE IN PBC AND PSC
    Keith Lindor; Fiscal Year: 1999
    Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are progressive chronic cholestatic liver diseases. Many patients eventually develop cirrhosis and/or portal hypertension with death caused by hepatic failure unless ..
  72. Preparative irradiation for hepatocyte transplantation
    Chandan Guha; Fiscal Year: 2009
    Hepatocyte transplantation (HT) could be of major value in the treatment of both inherited and acquired liver diseases. However, benefits of this procedure are currently limited by the number of hepatocytes that can be transplanted ..
  73. Small Molecule Inhibitors of HBV/HCV Induced Liver Diseases
    Surendra Dheer; Fiscal Year: 2009
    ..Successful completion of the proposed research will have identified a new drug candidate that can be further developed for prevention and treatment of HBV/HCV induced liver diseases and/or HCC in humans.
  74. Hepatitis B virus e antigen expression
    Shuping Tong; Fiscal Year: 2004
    Hepatitis B virus (HBV) infects nearly 1/10th of the world population and causes severe liver diseases including cancer...
  75. Gene delivery to bile duct epithelial cells in mice
    Vladimir Subbotin; Fiscal Year: 2001
    Primary biliary cirrhosis and primary sclerosing cholangitis are irreversible liver diseases of unknown etiology with no available treatment or preventive therapy, and only liver transplantation can prolong life of patients with disease ..